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ABSTRACT  94 
Purpose: Acrylamide was classified as ‘probably carcinogenic’ to humans in 1994 by the International 95 
Agency for Research on Cancer. In 2002, public health concern increased when acrylamide was 96 
identified in starchy, plant-based foods, processed at high temperatures. The purpose of this study was 97 
to identify which food groups and lifestyle variables were determinants of hemoglobin adduct 98 
concentrations of acrylamide (HbAA) and glycidamide (HbGA) in 801 non-smoking postmenopausal 99 
women from 8 countries in the European Prospective Investigation into Cancer and Nutrition (EPIC) 100 
cohort.  101 
Methods: Biomarkers of internal exposure were measured in red blood cells (collected at baseline) by 102 
HPLC/MS/MS (high-performance liquid chromatography/tandem mass spectrometry). In this cross-103 
sectional analysis four dependent variables were evaluated: HbAA, HbGA, sum of total adducts 104 
(HbAA+HbGA), and their ratio (HbGA/HbAA). Simple and multiple regression analyses were used to 105 
identify determinants of the four outcome variables. All dependent variables (except HbGA/HbAA), 106 
and all independent variables were log-transformed (log2) to improve normality. Median (25th-107 
75thpercentile) HbAA and HbGA adducts levels were 41.3 (32.8-53.1) pmol/g Hb and 34.2 (25.4-46.9) 108 
pmol/g Hb, respectively.  109 
Results: The main food group determinants of HbAA, HbGA, HbAA+HbGA were biscuits, crackers, 110 
and dry cakes. Alcohol intake and body mass index were identified as the principal determinants of 111 
HbGA/HbAA. The total percent variation in HbAA, HbGA, HbAA+HbGA, and HbGA/HbAA 112 
explained in this study was 30%, 26%, 29%, and 13%, respectively.  113 
Conclusions: Dietary and lifestyle factors explain a moderate proportion of acrylamide adduct variation 114 
in non-smoking postmenopausal women from the EPIC cohort. 115 
Key words (4 to 6): acrylamide; glycidamide; hemoglobin adducts; biomarkers; diet; nutrition.  116 
  117 
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INTRODUCTION  118 
Acrylamide was identified in food in 2002, and is mainly formed through the Maillard reaction whereby 119 
a carbonyl compound (a reducing sugar, such as glucose or fructose) reacts with the amino group of 120 
asparagine processed at high temperatures (>120 ºC; i.e. frying, baking, or roasting) [1, 2]. Nevertheless, 121 
acrylamide has also been found in foods cooked at temperatures lower than 100ºC (e.g. prune juice) [3]. 122 
Thus, levels of acrylamide in foods depend on factors such as temperature and length of cooking time, 123 
water content, and the amount of both reducing sugars and asparagine levels present in foods [4]. 124 
Freisling et al. assessed the principal food group determinants of acrylamide intake based on a 24-h 125 
dietary recall (24hDR) in 13,486 men and 23,508 women from the European Prospective Investigation 126 
into Cancer and Nutrition (EPIC) cohort, and identified bread, crisp bread, rusks, coffee, and potatoes 127 
[5].  128 
Once acrylamide is consumed, it is absorbed in the gastrointestinal tract and, via the circulation, is 129 
distributed to peripheral tissues [6, 7]. In the body, acrylamide is metabolized to glycidamide mainly by 130 
the cyp2e1 enzyme complex, and is conjugated with reduced glutathione for elimination. Acrylamide is 131 
neurotoxic in animals and in humans, but only glycidamide is considered to have mutagenic and 132 
genotoxic properties [1, 8]. As a consequence of animal and in vitro studies, the International Agency 133 
for Research on Cancer (IARC) classified acrylamide as ‘probably carcinogenic’ to humans [9].  134 
Acrylamide and glycidamide can bind to N-terminal valine of hemoglobin (Hb) in red blood cells, and 135 
form adducts, both of which are considered valid biomarkers that reflect human internal exposure within 136 
the last 120 days (the average lifespan of erythrocytes) [1, 10]. Tobacco smoking is an important source 137 
of acrylamide exposure, and smokers have been observed to have mean Hb adducts levels three to four 138 
times higher than non-smokers [11–13]. 139 
Two previous EPIC studies evaluated biomarkers of acrylamide measured as acrylamide and 140 
glycidamide Hb-adducts (HbAA and HbGA, respectively). The first study, published by Vesper et al., 141 
aimed to determine acrylamide exposure variability (both at the individual- and group/country-level) in 142 
240 men and 270 women, and at the same time, determine which non-dietary factors could play a role 143 
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in this variability [14]. The second study, published by Ferrari et al., was conducted with the intention 144 
to compare HbAA and HbGA levels with total estimated dietary acrylamide intakes assessed using 145 
dietary questionnaires (DQs), and a 24hDR in 240 men and 270 women to estimate the validity of the 146 
EPIC dietary acrylamide assessment [15]. The main objective of the present study, which differed from 147 
the two former EPIC studies, was to identify which food groups and lifestyle factors (assessed through 148 
country-specific DQs and lifestyle questionnaires) were determinants of HbAA and HbGA 149 
concentrations in a subgroup of non-smoking postmenopausal women from the EPIC cohort. The 150 
relation between intakes of several food items using DQs, and HbAA and HbGA adducts levels has been 151 
previously evaluated in three different studies [16–18]. 152 
MATERIALS AND METHODS 153 
Study population and data collection 154 
The EPIC study comprises 23 research centers in 10 European countries, and was designed to evaluate 155 
the relation between nutrition and lifestyle factors and the incidence of cancer and other chronic diseases. 156 
The present study includes 8 of the 10 participating EPIC countries: France, Germany, Spain, the United 157 
Kingdom (UK), Greece, Italy, The Netherlands, and Sweden (Umeå). Norway and Denmark did not 158 
participate in this analysis (EPIC-Denmark published their results separately as the Diet, Cancer, and 159 
Health cohort) [17]. 160 
The methodology of the EPIC study has been previously described [19]; all local ethics committees, 161 
and/or the IARC ethical review boards approved the study. Briefly, recruitment started between 1992-162 
1998, and all EPIC participants provided information on habitual diet through country-specific validated 163 
DQs, referring to the year before recruitment. Information on tobacco smoking, physical activity, and 164 
education were assessed using country-specific questionnaires. Anthropometric measures (height, 165 
weight, and waist or hip circumference) were obtained at baseline by trained personnel; however, 166 
participants from France and Oxford (UK) cohorts self-reported their height and weight. Umeå 167 
(Sweden), did not collect information on waist or hip circumference, and only 29% participants from 168 
France had information on these anthropometric measures.  169 
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Blood samples (serum, plasma, white blood cells, and erythrocytes) were collected at recruitment for 170 
385,747 of the over 500,000 EPIC participants, and were stored in liquid nitrogen (-196ºC) at the central 171 
biological bank located at IARC; blood samples from Umeå were kept in freezers (-80ºC) at local 172 
repositories [19]. The present study population comprises control women from two published ongoing 173 
nested case-control studies of acrylamide hemoglobin adducts levels and ovarian and endometrial 174 
cancers risk in EPIC [20, 21]. The selection of cases and controls for these two nested-case control 175 
studies followed the protocol that has been previously described by Cust et al. and Peeters et al. [22, 176 
23]. Briefly, two controls (free of cancer, with the exception of non-melanoma skin cancer) were 177 
randomly selected using an incidence density sampling protocol, for each case subject (ovarian or 178 
endometrial cancer case) at the time of diagnosis.  Matching criteria for both cases and controls included 179 
study center, menopausal status (premenopausal, postmenopausal, ‘undefined’), age at recruitment, (±6 180 
months), time of day of blood draw (±1 hour), fasting status (<3, 3-6, >6 hours). For the present study, 181 
only women who were postmenopausal at blood draw, and non-smokers at recruitment were selected, 182 
since it has been postulated that acrylamide may disrupt hormonal balance, and it is known that smoking 183 
contributes to Hb-adducts levels. Postmenopausal status refers to women who reported having had the 184 
last menstrual period more than 1 year before recruitment, or when they were more than 55 years old 185 
[23]. The category of non-smoking women includes those women who reported being never smokers or 186 
having quit smoking 5 or more years before recruitment. 187 
Thus, a total of 802 non-smoking postmenopausal control women (416 and 386 controls from the 188 
ovarian and the endometrial nested case-control studies, respectively) were available for the present 189 
study. One participant was excluded from analyses because she did not have information on HbGA 190 
adduct level, leaving a total of 801 observations  191 
Assessment of dietary acrylamide intake 192 
The methodology followed to create the EPIC acrylamide database has been previously described [15, 193 
24]. In brief, the EPIC acrylamide database was assembled using information on average acrylamide 194 
levels in foods from an EU monitoring database (maintained by the European Community Institute for 195 
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Reference Materials and Measurements; IRMM), and the frequency of consumption of these foods using 196 
country-specific DQs and the EPIC-Soft food classification. 197 
Measurement of acrylamide and glycidamide hemoglobin adducts  198 
The methodology to measure HbAA and HbGA in EPIC has been previously described [14, 15]. Briefly, 199 
300 μL of hemolysed erythrocytes were used to measure HbAA and HbGA, and were analyzed by 200 
HPLC/tandem mass spectrometry (HPLC/MS/MS) as has been published elsewhere [12, 25]. All blood 201 
samples were measured and analyzed in a randomized and blinded manner. Two independent adduct 202 
measures per sample were performed. Hemoglobin adduct concentrations were reported as the average 203 
of these two measurements relative to the amount of hemoglobin. The detection limits for this method 204 
were 3 and 4 pmol/g Hb for HbAA and HbGA, respectively. Additionally, 42 (5%) blood samples from 205 
the same participants were sent in duplicate to evaluate the reproducibility of the hemoglobin adducts 206 
measurements. 207 
Statistical methods 208 
All continuous variables included in the analysis were assessed for normality using the Kolmogorov-209 
Smirnov test, and were log-transformed (log2) in order to reduce skewness. To account for zeroes in 210 
dietary and lifestyle variables, a log2(x + 0.1) transformation was applied. Regarding adduct values, four 211 
outcomes were evaluated: log-transformed HbAA adducts (log2HbAA), log2HbGA, sum of total adducts 212 
[log2(HbAA + HbGA)], and HbGA/HbAA ratio. Simple and multiple linear regression analyses were 213 
used to assess the associations between each of the four outcome variables and food consumption and 214 
lifestyle data. 215 
The following dietary variables and food groups were evaluated to build the HbAA, HbGA, and 216 
HbAA+HbGA final models: total energy, total carbohydrates, total fat, total fiber, total proteins, starch, 217 
potatoes, ‘vegetables’, ‘fruits, nuts and seeds’, ‘cereal and cereal products’, ‘meat and meat 218 
products’[26], ‘cakes and biscuits’, ‘flour, flakes, starches, and semolina’, ‘pasta, rice, and other grains’, 219 
‘bread, crisp bread, and rusks’, ‘breakfast cereals’, ‘salty biscuits, aperitif biscuits, and crackers’, ‘dry 220 
cakes and biscuits’, ‘bread’, ‘pastries’, ‘olives’, ‘deep frying fats’, ‘chocolate, candy, paste, confetti’, 221 
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‘snacks’, ‘bread, and pizza dough’, ‘olive oil’, ‘coffee’, ‘decaffeinated coffee’, and ‘tea’. Then, a 222 
correlation matrix was performed to identify interdependency between dietary variables. Variables that 223 
were not correlated (r <0.6), that were matching factors for both nested case-control studies (country 224 
was used instead of center due to the number of observations), and ‘type of control’ (endometrial, 225 
ovarian control) were selected for building the final models. Lifestyle variables such as alcohol intake 226 
(g/day) and body mass index (kg/m2; BMI) were also investigated as they may affect the activity of 227 
Cyp2e1 [5, 27]. 228 
Stepwise selection was used to build models for HbAA, HbGA, and HbAA+HbGA adduct outcome 229 
variables. Matching factor and ‘type of control’ variables were forced to be included in the stepwise 230 
selection, and covariates were included in the model if they met the 0.10 significance level. Stepwise 231 
selection was also performed with all food items energy-adjusted using the residual method [28], but 232 
according to the Akaike Information Criterion (AIC) [29], these models were not optimal compared to 233 
those without energy-adjusted food items. 234 
Lifestyle variables such as physical activity using the Cambridge index [30], education level (none, 235 
primary, technical/professional, secondary, and higher education), history of diabetes (yes, no, 236 
unknown), ever use of oral contraceptives (OCs), and ever use of hormone replacement therapy (HRT) 237 
were also evaluated; however, were not included in HbAA, HbGA, and HbAA+HbGA final models 238 
because they did not have an effect on β-estimates.  239 
The HbGA/HbAA ratio model only included lifestyle variables described above (BMI, physical activity, 240 
education level, history of diabetes, OCs use, HRT use, and alcohol intake), since the ratio of 241 
HbGA/HbAA may reflect the metabolism of acrylamide to glycidamide.  242 
Intraclass correlation coefficients (ICC) were estimated to evaluate the reproducibility of acrylamide 243 
measurements using 42 duplicate blood samples from the same participants [31]. Analyses stratified by 244 
alcohol intake (never drinkers, drinkers), by BMI (<25, 25-30, ≥30 kg/m2), and by European region 245 
(Northern countries: the UK, The Netherlands, Germany, Sweden; Southern countries: France, Italy, 246 
Spain, Greece) were also performed. A Wilcoxon signed-rank test was used to assess differences in Hb-247 
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adducts levels by alcohol intake, BMI, and second-hand smoke exposure (SHS). Variables for SHS were 248 
not evaluated in final models due to the large number of missing values (>50%). R square (R2) values 249 
were used to describe the percent variation in Hb-adduct levels explained by the independent variables. 250 
Partial R2 values for each of the selected variables in the models were estimated using Type II sums of 251 
squares. Pearson’s correlation coefficients for continuous variables were also estimated. To test whether 252 
the slope of a regression line differed significantly from zero, Student’s t statistics and the corresponding 253 
P-values were used. All statistical tests were evaluated at α-level 0.05.  254 
All analyses were performed using SAS v. 9.1 (Cary, North Carolina, USA). Graphics were created 255 
using R v. 3.1.  256 
RESULTS 257 
Correlation Matrix 258 
Total carbohydrates was correlated with total fiber, total proteins, starch, and ‘cereal and cereal 259 
products’. Total fat was correlated with total proteins. Starch was correlated with ‘cereal and cereal 260 
products’. Thus, total carbohydrates, total fat, and starch were excluded from the analyses because these 261 
were larger groups of foods.  262 
Dietary acrylamide intake and baseline characteristics 263 
The median (25th-75th percentile) acrylamide intake at baseline based on DQ information was 20.3 (13.5-264 
29.9) μg/day. The median (25th-75th percentile) estimated dietary acrylamide in relation to body weight 265 
was 0.3 (0.2-0.5) μg/kg-body weight/day. The highest median intakes were found in the UK, the 266 
Netherlands, and Germany, whereas Italy had the lowest median intake (Table1).  267 
The median (25th-75th percentile) age in the present subcohort of women was 59 (54-63) years. Means 268 
and standard deviations, as well as medians and 25th-75th percentiles are presented for all dietary and 269 
lifestyle variables that were used in all analyses (Supplemental Table1). 270 
Hemoglobin adducts of acrylamide and glycidamide 271 
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The ICC for the present study based on 42 duplicates was 0.96 for HbAA and 0.95 for HbGA.  272 
The median (25th-75th percentile) HbAA and HbGA adducts level were 41.3 (32.8-53.1) and 34.2 (25.4-273 
46.9) pmol/g of Hb, respectively (Table1). The highest median HbAA adduct level was observed in the 274 
UK, The Netherlands, and Spain, while Greece had the lowest HbAA levels, followed by Italy. 275 
Regarding HbGA adduct levels, the highest medians were found in the UK, Spain, and The Netherlands, 276 
and the lowest median was also found in Greece and Italy (Table1). The geometric means for HbAA 277 
and HbGA adducts in the total dataset were 5.3 and 5.1 pmol/g Hb respectively (data not shown). Values 278 
for HbAA+HbGA, and HbGA/HbAA by EPIC country are also presented in Table 1.  279 
Regarding differences in Hb-adducts levels by alcohol intake and by BMI, only the ratio HbGA/HbAA 280 
differed (never vs ever drinkers, P-value <0.0001; <25, 25 to <30, ≥30 kg/m2, P-value <0.0001) (Figure 281 
1, and Figure 2 respectively). No statistically significant differences in Hb-adduct levels were observed 282 
between women who reported being exposed to SHS (n=95) and who were not exposed (n=149) (data 283 
not shown).  284 
Simple linear regression analyses 285 
The crude Pearson’s correlation coefficient between log2-acrylamide intake and log2HbAA was 0.36, 286 
between log2-acrylamide intake and log2HbGA was 0.35, between log2-acrylamide intake and 287 
log2(HbAA+HbGA) was 0.37, and between log2HbAA and log2HbGA was 0.86 (all P-values <0.0001). 288 
Log2HbAA was inversely associated with BMI (P-value <0.0001) and positively associated with alcohol 289 
intake (P-value= 0.04). A statistically significant inverse association was found between HbGA/HbAA 290 
ratio and alcohol intake (P-value <0.0001), whereas a positive association was observed between 291 
HbGA/HbAA ratio and BMI (P-value <0.0001) (Table 2).  292 
Multiple linear regression analyses 293 
Four multivariable linear regression analyses (all models included country, age at recruitment, date of 294 
blood donation, fasting status, and type of control) were performed for each of the four outcome 295 
variables with the aim to identify independent determinants of log2HbAA, log2HbGA, 296 
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log2(HbAA+HbGA), and HbGA/HbAA (Table 3). Analyses stratified by alcohol intake and by BMI 297 
were performed, but no major differences were observed, thus, only overall results are presented.  298 
The HbAA model explained 30% of the variation in HbAA levels, and the food groups ‘salty biscuits, 299 
aperitif biscuits, crackers’, ‘dry cakes, biscuits’, and ‘vegetables’ were statistically significant positively 300 
associated with log2HbAA values, whereas ‘tea’ was inversely associated . 301 
The HbGA model explained 26% of the variation of HbGA levels, and the following groups were 302 
statistically significantly associated with HbGA-log levels: ‘salty biscuits, aperitif biscuits, crackers’, 303 
‘dry cakes, biscuits’, and ‘deep frying fats’. Alcohol intake was inversely associated with log2HbGA 304 
values.  305 
The HbAA+HbGA model explained 29% of the variation of the sum of total adducts levels, and only 306 
‘salty biscuits, aperitif biscuits, crackers’, ‘dry cakes, biscuits’, and ‘deep frying fats’ were significantly 307 
associated with the sum of total adducts levels.  308 
The HbGA/HbAA model explained 13% of the variation in HbGA/HbAA ratio, and BMI was positively 309 
associated, whereas alcohol consumption at recruitment was inversely associated with the HbGA/HbAA 310 
ratio. No other lifestyle variable explained variation in the ratio. 311 
Multiple linear regression analyses were also performed by European region (data not shown). The 312 
three different models from the northern countries explained a higher variation in HbAA, HbGA, and 313 
HbAA+HbGA levels than the southern countries; however, the food groups identified as dietary 314 
determinants of Hb-adducts levels by European region were, in general, similar to those presented in 315 
table 3.  316 
DISCUSSION 317 
The present study was carried out with the aim to identify independent determinants of HbAA, HbGA, 318 
HbAA+HbGA, and HbGA/HbAA. We investigated these associations in a cross-sectional study of 801 319 
non-smoking postmenopausal women from the EPIC cohort. The most important determinants of 320 
HbAA, HbGA, and HbAA+HbGA adduct levels were ‘salty biscuits, aperitif biscuits, and crackers’, 321 
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and ‘dry cakes and biscuits’; whereas alcohol intake and BMI (inversely and positively associated, 322 
respectively) were identified as the two main determinants of HbGA/HbAA ratio.  323 
To our knowledge, there are only three published studies that evaluated the relation between specific 324 
food group determinants and Hb-adducts of acrylamide and glycidamide, and all of them obtained 325 
dietary information through DQs [16–18]. The first study was based on a Norwegian population, and 326 
included 19 men and 31 women (n=50) of which 14% of the subjects were smokers. The second study 327 
comprised 296 female, non-smoking, pre- and postmenopausal women from the Nurses’ Health Study 328 
II (NHS-II). The Danish study, similar to the present study, was based on postmenopausal women who 329 
reported being non-smokers at baseline (n=537).  330 
The current study had the highest estimated intake of acrylamide compared to the Norwegian and the 331 
NHS-II studies. The Norwegian study reported a median acrylamide intake of 12.8 µg/day among non-332 
smoking women (in EPIC, 20.3 µg/day), and the NHS-II study reported a mean energy-adjusted intake 333 
of 19.3 µg/day (in EPIC, 21.9 µg/day). The Danish study did not report information on overall dietary 334 
acrylamide intake.  335 
Blood samples from both EPIC and NHS-II studies were measured in the same laboratory using the 336 
same protocol. Likewise, the Norwegian and the Danish studies shared the same methodology [16, 17]. 337 
The median adduct levels for HbAA and HbGA in the present study (41.3 and 34.2 pmol/g of Hb, 338 
respectively) were higher than the values reported in the Norwegian (36.8 and 18.2 pmol/g of Hb), and 339 
the Danish (35 and 21pmol/g of Hb) studies; however, the NHS-II study reported the highest values of 340 
Hb-adducts (43.9 and 49.4 pmol/g of Hb). The NHS-II study also had the highest median values of 341 
HbGA/HbAA (1.10), compared to the Norwegian (0.49), and the present (0.8) study.  342 
The correlation between estimated acrylamide intake (based on DQs), and Hb-adducts of acrylamide 343 
and glycidamide was low (ranging from 0.08 to 0.43) in most studies, including EPIC [15, 16, 32–34]. 344 
The NHS-II study reported moderate correlations between acrylamide intake and HbAA or HbGA (0.19-345 
0.35). These differences could be due to errors in dietary assessment methods, and to incomplete data 346 
on acrylamide content in food composition databases. The NHS-II acrylamide database was mainly 347 
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based on values from the FDA’s Exploratory Analysis of Acrylamide in Foods, but specific foods that 348 
were frequently consumed in the study were further analyzed, such as different brands of breakfast 349 
cereals, dried food, bread, and potatoes chips among others [18].   350 
The main food group determinants of Hb-adducts (HbAA, HbGA, and HbAA+HbGA) in the present 351 
study were ‘salty biscuits, aperitif biscuits, and crackers’, and ‘dry cakes, and biscuits’; whereas 352 
Freisling et al. reported that ‘bread, crisp bread, and rusks’, ‘coffee’, and ‘potatoes’, were the main 353 
determinants of dietary acrylamide intake (based on a single 24 hDR) in a different subgroup of EPIC 354 
men and women [5]. Coffee was selected in the stepwise procedure as one of the food determinants of 355 
HbGA, and HbAA+HbGA in the present study, but was not statistically significant. Inverse associations 356 
between ‘tea’ and Hb-adduct levels (HbAA, HbGA, and HbAA+HbGA) were observed in the present 357 
study. This result may be explained by the possible effect of tea polyphenols, which have been observed 358 
to decrease HbAA levels in animals [35].  The variable ‘vegetables’ was selected as a determinant of 359 
log2HbAA; however, this result might has been confounded by other acrylamide containing foods, since 360 
‘vegetables’ includes all forms of cooking methods (including frying and baking). The food groups 361 
‘bread, crisp bread, rusks’, and ‘potatoes’ were not selected in any of the models presented in this study; 362 
however the possible effect of ‘potatoes’, especially fried potatoes, might have been represented by the 363 
variable ‘deep frying fats’. It is worth noting that the present study was evaluating adducts levels, 364 
whereas the Friesling et al. study was evaluating acrylamide intake based on 24 hDR. Further, 365 
differences in the results of these two EPIC analyses may reflect differences in the subpopulation studied 366 
(e.g, age distribution, sex, menopausal status).  367 
The Norwegian study identified as dietary determinants of HbAA levels ‘potatoes’, ‘chips/snacks’, 368 
‘crisp bread’, and ‘jam/preservatives. Furthermore, ‘chips/snacks’, and ‘crisp bread’ were also 369 
recognized as determinants of HbAA+HbGA. Similar to EPIC, the NHS-II study also identified dietary 370 
determinants of HbAA, HbGA, and HbAA+HbGA; but the food groups were different from the 371 
determinants observed in the present study. The Danish study reported ‘coffee’ to be associated with 372 
HbAA and HbGA, ‘chips’ to HbAA, and ‘biscuits/crackers’ to HbGA levels. Dietary habits are different 373 
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between the US and European countries, so direct comparison of food groups as determinants of HbAA 374 
levels may not be possible.  375 
The proportion of response variation (R2) explained by food groups and/or lifestyle variables in the 376 
present study varied from 13% in the HbGA/HbAA model to 30% for HbAA. The Danish study obtained 377 
a response variation of 17% and 12% in the HbAA and HbGA models respectively; however the highest 378 
response variations explained were obtained in the Norwegian study (48% in the HbAA, and 37% in the 379 
HbAA+HbGA model) [16, 17]. The NHS-II study did not report this information [18]. 380 
The main difference between our study and the other three published studies is that prior analyses only 381 
included dietary variables that were suspected to be sources of acrylamide intake. The current study 382 
included both known sources of dietary acrylamide together with lifestyle variables, such as alcohol 383 
intake and BMI, with the intention to better describe the independent determinants of Hb-adducts and 384 
their ratio in non-smoking individuals. Diet is complex, and interactions between acrylamide and food 385 
ingredients are possible (i.e, acrylamide uptake in humans has been hypothesized to be impaired by a 386 
diet rich in proteins) [26]. Likewise, it has been suggested that alcohol intake and BMI may influence 387 
the activity of Cyp2e1, the enzyme complex that metabolizes acrylamide to glycidamide. This enzyme 388 
is involved in alcohol metabolism mainly when alcohol concentrations in the blood are high. It has been 389 
hypothesized that alcohol may compete with acrylamide as a substrate [36]. This could partially explain 390 
the results observed in the present study; in which higher alcohol intake was inversely associated with 391 
HbGA and HbGA/HbAA, as has been reported in other studies [14, 36]. The mechanism by which BMI 392 
may influence acrylamide metabolism is still unclear, but similar to the present study, other studies have 393 
observed that BMI was positively associated with the ratio HbGA/HbAA, and negatively associated 394 
with HbAA [14, 37, 38]. Recently, statistically significant differences in the ratio of HbGA/HbAA 395 
between vegetarians and non-vegetarians have been reported, suggesting that dietary factors may also 396 
contribute to acrylamide/glycidamide metabolism [39]. 397 
The present study had the largest sample size compared to the previous published papers, and the 398 
laboratory methods used to quantify both acrylamide and glycidamide hemoglobin adducts were 399 
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standardized and followed rigorous quality assurance/quality control [12]. Tobacco is one of the most 400 
important sources of acrylamide, and it is well-established that cigarette smoke influences Hb-adducts 401 
levels (smokers have mean HbAA levels at least three to four times higher than non-smokers) [11, 14]. 402 
Moreover, it has been hypothesized that acrylamide may influence hormonal homeostasis [40–42]. 403 
Thus, the present study was designed to reduce confounding by these factors, and only those women 404 
who reported being postmenopausal and never smokers were included in the study. Further, limitations 405 
derived from using estimates of dietary acrylamide intake, as described above, were avoided in the 406 
present analysis of food groups and biomarkers levels.  407 
There are some limitations that should be acknowledged: a) Hb-adducts of acrylamide and glycidamide 408 
are valid biomarkers for acrylamide exposure and internal dose; however, these adducts reflect levels of 409 
acrylamide and glycidamide during the average lifespan of erythrocytes, which is around 120 days [1, 410 
10], and all dietary and lifestyle variables in EPIC were assessed through DQs that referred to the 411 
previous year before recruitment [19]. b) Cooking methodology, which influences acrylamide levels in 412 
food, was not recorded in some EPIC centers; however, relevant information on food preparation was 413 
available for potatoes (except in Italy), bread, and breaded meats [15, 24]. c) Only one baseline blood 414 
sample was collected for each participant. d) Acrylamide content in foods may vary seasonally [43], 415 
which was not accounted for in our analyses; nevertheless, all models were adjusted for date of blood 416 
extraction to minimize this effect. (e) Ferrari et al. described variations in dietary patterns across EPIC 417 
countries [15], and this may have influenced Hb-adducts levels and our prediction models, although all 418 
models included country to adjust for country-level effects (i.e. questionnaire design, dietary habits). f) 419 
SHS could not be evaluated in our statistical models due to the large number of missing values (>50%); 420 
however, in a subset of women from the current study, no statistically significant differences in Hb-421 
adduct levels were observed between women who were exposed to SHS and who were not exposed to 422 
SHS. 423 
To conclude, dietary food group and lifestyle variables explain a moderate proportion of HbAA and 424 
HbGA adduct level variation in 801 postmenopausal non-smoking women in the EPIC cohort. The main 425 
food groups determinants of HbAA, HbGA, and HbAA+HbGA were ‘Salty biscuits, aperitif biscuits, 426 
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and crackers’, and ‘dry cakes, and biscuits’. Alcohol intake and BMI were identified as the principal 427 
determinants for the ratio HbGA/HbAA levels. In this regard, future studies assessing associations 428 
between acrylamide and disease risk should take into consideration the use of both biomarkers of 429 
acrylamide exposure (HbAA and HbGA), in addition to alcohol intake and BMI.   430 
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Table 1. Estimated dietary acrylamide intake and hemoglobin acrylamide and glycidamide adducts levels by EPIC country in a subgroup of non-smoking postmenopausal women  
 
Total 
observations  
Endometrial 
controls 
Ovarian 
controls 
  
Acrylamide 
intake HbAA          
pmol/g of Hb 
HbGA        
pmol/g of Hb 
HbAA+HbGA           
pmol/g of Hb 
 Ratio of 
HbGA/HbA
A 
 
Acrylamide 
intake (µg/day) 
Acrylamidea 
intake (µg/day) 
µg/ kg-body 
weight/day 
EPIC country n (%) n (%) n (%) Median (QR) Median (QR) Median (QR) Median (QR) Median (QR) Median (QR) Median (QR) 
France 
65 (8) 35 (9) 30 (7) 
20.0 (14.5- 
25.6) 
17.6 (13.5- 
21.6) 
0.3 (0.2- 0.4) 
38.5 (34.2- 
47.3) 
29.4 (24.6- 
36.8) 
66.4 (60.1- 82.9) 0.7 (0.7- 0.8) 
Italy 
126 (16) 74 (19) 52 (12) 8.6 (5.5- 11.5) 7.8 (4.1- 10.7) 0.1 (0.1- 0.2) 
35.8 (26.7- 
44.9) 
28.9 (21.9- 
38.2) 
64.7 (49.8- 87.7) 0.8 (0.7- 0.9) 
Spain 
127 (16) 72 (19) 55 (13) 16.6 (9.8- 25.9) 
19.0 (13.0- 
25.4) 
0.2 (0.1- 0.4) 
42.4 (33.8- 
53.8) 
39.8 (28.6- 
48.6) 
82.4 (62.9- 101.5) 0.9 (0.8- 1.0) 
United 
Kingdom 
153 (19) 59 (15) 94 (23) 
31.4 (23.8- 
40.4) 
30.5 (24.2- 
39.5) 
0.5 (0.3- 0.6) 
55.6 (44.4- 
69.0) 
47.1 (35.2- 
61.3) 
102.9 (83.1- 
133.4) 
0.8 (0.7- 1.0) 
The 
Netherlands 
116 (14) 38 (10) 78 (19) 
28.8 (19.4- 
40.0) 
30.0 (22.1- 
40.4) 
0.4 (0.3- 0.6) 
45.3 (37.2- 
54.4) 
38.6 (29.5- 
51.7) 
80.9 (68.0- 105.2) 0.9 (0.7- 1.0) 
Greece 
59 (7) 16 (4) 43 (10) 
17.7 (14.4- 
21.9) 
19.1 (17.5- 
22.8) 
0.2 (0.2- 0.3) 
26.4 (21.1- 
35.3) 
22.0 (16.5- 
31.8) 
50.4 (40.1- 67.1) 0.9 (0.7- 1.0) 
Germany 
102 (13) 56 (15) 46 (11) 
22.8 (18.5- 
29.5) 
24.9 (19.9- 
29.2) 
0.3 (0.2- 0.5) 
36.2 (29.7- 
43.8) 
29.3 (23.1- 
38.5) 
67.2 (53.0- 78.5) 0.8 (0.7- 0.9) 
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Sweden 
53 (7) 34 (9) 19 (5) 
18.3 (14.8- 
21.0) 
22.6 (20.5- 
25.0) 
0.3 (0.2- 0.3) 
38.5 (34.9- 
46.9) 
34.6 (25.9- 
42.2) 
72.8 (62.9- 87.8) 0.9 (0.8- 1.0) 
Total 801 384 417 20.3 (13.5-29.9) 21.9 (14.6-29.2) 0.3 (0.2-0.5) 41.3 (32.8-53.1) 34.2 (25.4-46.9) 75.5 (58.5-100.0) 0.8 (0.7-1.0) 
EPIC, European Prospective Investigation into Cancer and Nutrition; QR, quartile range, HbAA, hemoglobin adducts of acrylamide; HbGA, hemoglobin adducts of glycidamide; Hb, 
hemoglobin 
a Energy-adjusted using the residual method 
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Table 2. Simple linear regression with β-estimates for the association between dietary and lifestyle variables and log-transformed (log2) 
HbAA, HbGA, HbAA+HbGA, and HbGA/HbAA. 
Variables 
Log2HbAA Log2HbGA HbAA+HbGA HbGA/HbAA 
β P-value β P-value β P-value β P-value 
Acrylamide intake (µg/day) 0.20 <.0001 0.23 <.0001 0.21 <.0001 0.02 0.02 
Age at recruitment (y) -0.003 0.26 0.001 0.79 -0.002 0.60 0.002 0.03 
Body mass index (kg/m2) -0.32 <.0001 -0.01 0.91 -0.18 0.02 0.17 <.0001 
Alcohol intake (g/day) 0.01 0.04 -0.01 0.09 0.002 0.79 -0.01 <.0001 
Total dietary fiber (g/day) 0.17 <.0001 0.15 0.002 0.16 0.0001 -0.01 0.53 
Total proteins (g/day) 0.15 0.0003 0.18 0.0003 0.17 0.0002 0.01 0.30 
Meat and meat products (g/day) -0.02 0.20 0.00 0.78 -0.01 0.58 0.01 0.01 
Potatoes and other tubers (g/day) 0.04 <.0001 0.05 <.0001 0.05 <.0001 0.01 0.16 
Vegetables (g/day) 0.05 0.01 0.03 0.17 0.04 0.03 -0.01 0.10 
Fruits, nuts, and seeds (g/day) -0.02 0.21 -0.02 0.32 -0.02 0.25 0.002 0.78 
Olives (g/day) -0.05 <.0001 -0.05 <.0001 -0.05 <.0001 0.001 0.79 
Cereal and cereal products (g/day) -0.02 0.51 -0.02 0.47 -0.02 0.51 0.00003 1.00 
Flour, flakes, starches, semolina (g/day) -0.07 <.0001 -0.06 <.0001 -0.06 <.0001 0.004 0.25 
Pasta, rice, other grains (g/day) -0.02 0.02 -0.03 0.01 -0.02 0.01 -0.002 0.48 
Bread, crisp bread and rusks (g/day) -0.04 0.01 -0.03 0.10 -0.04 0.03 0.007 0.19 
Breakfast cereals (g/day) 0.04 <.0001 0.03 <.0001 0.04 <.0001 -0.002 0.34 
Salty biscuits, aperitif biscuits, crackers (g/day) 0.04 <.0001 0.04 <.0001 0.04 <.0001 -0.003 0.21 
Dry cakes, biscuits (g/day) 0.02 0.0003 0.03 <.0001 0.03 <.0001 0.005 0.02 
Pastries (g/day) -0.02 0.06 -0.04 0.0001 -0.03 0.004 -0.01 <.0001 
Cakes, biscuits (g/day) 0.03 0.0003 0.04 <.0001 0.03 <.0001 0.004 0.14 
Chocolate, candy, paste, confetti (g/day)  0.03 <.0001 0.03 <.0001 0.03 <.0001 0.001 0.51 
Confectionery non-chocolate, candied fruits 
(g/day) 0.02 0.004 0.03 0.004 0.02 0.003 0.002 0.41 
Snacks (g/day) 0.05 <.0001 0.06 <.0001 0.05 <.0001 0.002 0.35 
Olive oil (g/day) -0.04 <.0001 -0.04 <.0001 -0.04 <.0001 0.002 0.33 
Deep frying fats (g/day) 0.03 0.04 0.03 0.03 0.03 0.03 0.004 0.36 
Tea (ml/day) 0.02 <.0001 0.02 0.0001 0.02 <.0001 -0.002 0.06 
Coffee (ml/day) 0.02 0.001 0.02 0.01 0.02 0.002 -0.0001 0.98 
Decaffeinated coffee (ml/day) 0.02 <.0001 0.03 <.0001 0.03 <.0001 0.002 0.24 
Energy intake (kcal/day) 0.13 0.01 0.13 0.02 0.13 0.01 -0.0001 0.99 
HbAA, hemoglobin adducts of acrylamide, HbGA, hemoglobin adducts of glycidamide 
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All independent variables were log-transformed (log2) to improve normality. 
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Table3. Multiple linear stepwise regression with β-estimates and standard errors for the association between dietary and lifestyle 
variables and log-transformed (log2) HbAA, HbGA, HbAA+HbGA, and HbGA/HbAA. 
Hemoglobin 
Dietary and/or life style variables β (SE) P-value Partial R2 Model R2 
 adducts 
L
o
g
2
H
b
A
A
 
Salty biscuits, aperitif biscuits, crackers 0.03 (0.01) 0.0001 0.01 
0.3 
Dry cakes, biscuits 0.02 (0.01) 0.003 0.01 
Tea -0.01 (0.005) 0.02 0.01 
Vegetables 0.05 (0.02) 0.02 0.005 
BMI -0.15 (0.07) 0.05 0.004 
Deep frying fats 0.04 (0.02) 0.08 0.003 
L
o
g
2
H
b
G
A
 
Dry cakes, biscuits 0.03 (0.01) 0.0001 0.02 
0.26 
Salty biscuits, aperitif biscuits, crackers 0.03 (0.01) 0.0002 0.01 
Alcohol at recruitment -0.02 (0.01) 0.01 0.01 
Deep frying fats 0.07 (0.03) 0.02 0.01 
Coffee 0.01 (0.01) 0.06 0.003 
Tea -0.01 (0.01) 0.07 0.003 
L
o
g
2
 (
H
b
A
A
+
H
b
G
A
) Salty biscuits, aperitif biscuits, crackers 0.03 (0.01) 0.0001 0.01 
0.29 
Dry cakes, biscuits 0.02 (0.01) 0.0005 0.01 
Tea -0.01 (0.005) 0.02 0.005 
Deep frying fats 0.05 (0.02) 0.03 0.004 
Fiber 0.07 (0.04) 0.05 0.003 
Coffee 0.01 (0.01) 0.08 0.003 
H
b
G
A
/H
b
A
A
  
BMI 0.14 (0.03) <0.0001 0.03 
0.13 
Alcohol at recruitment -0.01 (0.002) 0.00002 0.02 
Education level    
None reference - 
0.006 
Primary school completed -0.01 (0.02) 0.73 
Technical/professional school -0.02 (0.03) 0.51 
Secondary school -0.02 (0.03) 0.61 
Higher education -0.06 (0.03) 0.05 
Not specified 0.02 (0.05) 0.70 
Missing -0.04 (0.07) 0.53 
Ever use of OCs    
No reference -  
Yes -0.02 (0.01) 0.12 
0.003 
Missing 0.04 (0.06) 0.53 
Physical activity    
Inactive reference - 
0.003 
Moderately inactive 0.02 (0.02) 0.28 
Moderately active -0.02 (0.02) 0.29 
Active 0.01 (0.02) 0.77 
Missing -0.03 (0.09) 0.74 
Ever use of HRT    
No reference -  
Yes 0.004 (0.02) 0.81 
0.002 
Missing -0.05 (0.04) 0.22 
Diabetes    
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No reference -  
Yes 
-0.02 (0.03) 0.47 
0.001 
Missing -0.03 (0.07) 0.64 
SE, standard error; HbAA, hemoglobin adducts of acrylamide; HbGA, hemoglobin adducts of glycidamide; BMI, body mass index (kg/m2); 
HRT, hormonal replacement therapy; OC, oral contraceptive. 
All models are adjusted for country, age at recruitment (y), date of blood donation, fasting status (no, in between, yes), and type of control 
(endometrial, ovarian control). All independent continuous variables were log-transformed (log2) to improve normality. 
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Figure 1. Box-and-whisker plot of HbGA/HbAA ratio versus alcohol consumption (never drinkers, ever drinkers). 
Arrow marks significant differences between groups. P-value based on a Wilcoxon rank sum test. 
 
 
Figure 2. Box-and-whisker plot of HbGA/HbAA ratio versus body mass index (BMI; <25, 25-30, ≥30 
kg/m2).Arrow marks significant differences between groups. P-values based on a Wilcoxon rank sum test. 
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Supplemental table 1. Baseline characteristics of the 801 non-smoking postmenopausal women 
Variables Mean SD P5 P25 Median P75  P95 
Lifestyle variables         
Age at recruitment (y) 58.79 6.30 49.29 54.33 58.83 63.06 69.44 
Body Mass Index (kg/m2) 26.73 4.90 20.07 23.21 25.96 29.41 36.07 
Alcohol at recruitment (g/d) 6.04 8.63 0.00 0.18 2.13 8.87 24.26 
Dietary variables (g/day)        
Total dietary fiber 22.45 7.02 12.28 17.76 21.73 26.28 34.70 
Total proteins  83.02 25.34 45.70 65.42 81.00 97.23 128.04 
Meat and meat products  90.88 48.77 21.05 56.34 84.03 121.54 175.53 
Potatoes and other tubers  78.00 58.92 7.09 32.90 67.11 114.85 178.94 
Vegetables 215.85 139.33 56.35 114.68 183.18 292.20 472.48 
Olives 1.30 4.44 0.00 0.00 0.00 0.03 8.57 
Fruits, nuts, seeds  289.73 179.12 69.58 161.15 259.53 376.37 628.21 
Flour, flakes, starches, semolina 0.56 2.13 0.00 0.00 0.00 0.16 2.54 
Pasta, rice, other grains 58.64 56.09 3.36 20.03 41.86 80.12 176.62 
Cereal and cereal products 198.09 93.95 79.97 135.42 182.42 241.91 375.86 
Bread, crisp bread, rusks 116.16 65.97 28.80 69.50 104.77 152.00 234.88 
Breakfast cereals 17.25 45.85 0.00 0.00 0.00 11.17 115.10 
Salty biscuits, aperitif biscuits, crackers 2.14 5.10 0.00 0.00 0.22 2.14 11.43 
Dry cakes, biscuits 9.63 20.88 0.00 0.00 3.44 12.32 38.93 
Pastries 0.91 2.00 0.00 0.00 0.00 0.99 4.62 
Cakes and biscuits 46.57 47.92 0.00 15.35 34.43 63.76 128.57 
Chocolate, candy bars, paste, confetti 6.26 11.21 0.00 0.00 2.00 8.04 25.00 
Confectionery non-chocolate, candied fruits 2.57 7.10 0.00 0.00 0.13 1.67 12.90 
Snacks 2.29 9.26 0.00 0.00 0.00 0.21 10.01 
Olive oil 9.00 14.06 0.00 0.00 0.47 15.22 39.51 
Deep frying fats 0.32 1.04 0.00 0.00 0.00 0.00 2.03 
Tea 220.49 318.36 0.00 0.00 41.42 375.00 855.00 
Coffee 282.75 262.19 0.00 70.00 191.90 475.00 750.00 
Decaffeinated coffee 38.39 110.55 0.00 0.00 0.00 3.57 250.00 
Energy intake (kcal/day) 1,913.10 550.34 1,132.44 1,529.36 1,842.57 2,214.45 2,861.80 
SD, Standard deviation; P5, 5th percentile, P25, 25th percentile; P75, 75th percentile; P95, 95th percentile 
 
 
